Cargando…
Disease evolution in systemic juvenile idiopathic arthritis: an international, observational cohort study through JIRcohort
BACKGROUND: Systemic juvenile idiopathic arthritis (systemic JIA) is a severe disease with both systemic and joint inflammation. This study aims to identify predictors of disease evolution within the systemic JIA population enrolled in the Juvenile Inflammatory Rheumatism cohort (JIRcohort). METHODS...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485973/ https://www.ncbi.nlm.nih.gov/pubmed/37679749 http://dx.doi.org/10.1186/s12969-023-00886-9 |
_version_ | 1785102900947582976 |
---|---|
author | Wallimann, M. Bouayed, K. Cannizzaro, E. Kaiser, D. Belot, A. Merlin, E. Poignant, S. Wouters, C. Hofer, F. Saurenmann, T. Koryllou, A. Carlomagno, R. Mejbri, M. Hofer, M. Theodoropoulou, K. |
author_facet | Wallimann, M. Bouayed, K. Cannizzaro, E. Kaiser, D. Belot, A. Merlin, E. Poignant, S. Wouters, C. Hofer, F. Saurenmann, T. Koryllou, A. Carlomagno, R. Mejbri, M. Hofer, M. Theodoropoulou, K. |
author_sort | Wallimann, M. |
collection | PubMed |
description | BACKGROUND: Systemic juvenile idiopathic arthritis (systemic JIA) is a severe disease with both systemic and joint inflammation. This study aims to identify predictors of disease evolution within the systemic JIA population enrolled in the Juvenile Inflammatory Rheumatism cohort (JIRcohort). METHODS: Observational patient cohort study with 201 recruited children from 4 countries (3 European, 1 North Africa) from 2005 until 2019, using retrospectively (2005–2015) and prospectively (2015–2019) routine care collected data. RESULTS: Sixty-five patients with complete follow-up data for 24 months after first diagnosis were classified as monophasic (n = 23), polyphasic (n = 6) or persistent group (n = 36) corresponding to their evolution (unique flare, recurrent flares, or persistent disease activity respectively). The patients of the persistent group were more likely to have an earlier disease onset, before the age of 6 (OR 2.57, 95%-CI 0.70–9.46), persistence of arthritis at 12-months post-diagnosis (OR 4.45, 95%-CI 0.58–34.20) and higher use of synthetic DMARD (sDMARD, OR 5.28, 95%-CI 1.39–20.01). Other variables like global assessment by physician and by patient and C Reactive Protein levels at 12-months post-diagnosis were assessed but without any predictive value after adjusting for confounding factors. CONCLUSIONS: Our results suggest that the earlier disease onset, the persistence of arthritis throughout the first year of disease evolution and the need of sDMARD might predict a persistent disease course. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12969-023-00886-9. |
format | Online Article Text |
id | pubmed-10485973 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-104859732023-09-09 Disease evolution in systemic juvenile idiopathic arthritis: an international, observational cohort study through JIRcohort Wallimann, M. Bouayed, K. Cannizzaro, E. Kaiser, D. Belot, A. Merlin, E. Poignant, S. Wouters, C. Hofer, F. Saurenmann, T. Koryllou, A. Carlomagno, R. Mejbri, M. Hofer, M. Theodoropoulou, K. Pediatr Rheumatol Online J Research Article BACKGROUND: Systemic juvenile idiopathic arthritis (systemic JIA) is a severe disease with both systemic and joint inflammation. This study aims to identify predictors of disease evolution within the systemic JIA population enrolled in the Juvenile Inflammatory Rheumatism cohort (JIRcohort). METHODS: Observational patient cohort study with 201 recruited children from 4 countries (3 European, 1 North Africa) from 2005 until 2019, using retrospectively (2005–2015) and prospectively (2015–2019) routine care collected data. RESULTS: Sixty-five patients with complete follow-up data for 24 months after first diagnosis were classified as monophasic (n = 23), polyphasic (n = 6) or persistent group (n = 36) corresponding to their evolution (unique flare, recurrent flares, or persistent disease activity respectively). The patients of the persistent group were more likely to have an earlier disease onset, before the age of 6 (OR 2.57, 95%-CI 0.70–9.46), persistence of arthritis at 12-months post-diagnosis (OR 4.45, 95%-CI 0.58–34.20) and higher use of synthetic DMARD (sDMARD, OR 5.28, 95%-CI 1.39–20.01). Other variables like global assessment by physician and by patient and C Reactive Protein levels at 12-months post-diagnosis were assessed but without any predictive value after adjusting for confounding factors. CONCLUSIONS: Our results suggest that the earlier disease onset, the persistence of arthritis throughout the first year of disease evolution and the need of sDMARD might predict a persistent disease course. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12969-023-00886-9. BioMed Central 2023-09-07 /pmc/articles/PMC10485973/ /pubmed/37679749 http://dx.doi.org/10.1186/s12969-023-00886-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Wallimann, M. Bouayed, K. Cannizzaro, E. Kaiser, D. Belot, A. Merlin, E. Poignant, S. Wouters, C. Hofer, F. Saurenmann, T. Koryllou, A. Carlomagno, R. Mejbri, M. Hofer, M. Theodoropoulou, K. Disease evolution in systemic juvenile idiopathic arthritis: an international, observational cohort study through JIRcohort |
title | Disease evolution in systemic juvenile idiopathic arthritis: an international, observational cohort study through JIRcohort |
title_full | Disease evolution in systemic juvenile idiopathic arthritis: an international, observational cohort study through JIRcohort |
title_fullStr | Disease evolution in systemic juvenile idiopathic arthritis: an international, observational cohort study through JIRcohort |
title_full_unstemmed | Disease evolution in systemic juvenile idiopathic arthritis: an international, observational cohort study through JIRcohort |
title_short | Disease evolution in systemic juvenile idiopathic arthritis: an international, observational cohort study through JIRcohort |
title_sort | disease evolution in systemic juvenile idiopathic arthritis: an international, observational cohort study through jircohort |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485973/ https://www.ncbi.nlm.nih.gov/pubmed/37679749 http://dx.doi.org/10.1186/s12969-023-00886-9 |
work_keys_str_mv | AT wallimannm diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort AT bouayedk diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort AT cannizzaroe diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort AT kaiserd diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort AT belota diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort AT merline diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort AT poignants diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort AT woutersc diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort AT hoferf diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort AT saurenmannt diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort AT korylloua diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort AT carlomagnor diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort AT mejbrim diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort AT hoferm diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort AT theodoropoulouk diseaseevolutioninsystemicjuvenileidiopathicarthritisaninternationalobservationalcohortstudythroughjircohort |